179 related articles for article (PubMed ID: 12118761)
1. Early and late mortality after pleurodesis for malignant pleural effusion.
Bernard A; de Dompsure RB; Hagry O; Favre JP
Ann Thorac Surg; 2002 Jul; 74(1):213-7. PubMed ID: 12118761
[TBL] [Abstract][Full Text] [Related]
2. Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single-centre experience.
Leemans J; Dooms C; Ninane V; Yserbyt J
Respirology; 2018 Jun; 23(6):613-617. PubMed ID: 29320805
[TBL] [Abstract][Full Text] [Related]
3. Thoracoscopic talc pleurodesis for malignant pleural effusion.
Love D; White D; Kiroff G
ANZ J Surg; 2003; 73(1-2):19-22. PubMed ID: 12534732
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment.
Habal P; Omran N; Jankovicova K; Krejsek J; Mandak J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):234-41. PubMed ID: 25059234
[TBL] [Abstract][Full Text] [Related]
5. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
Thomas R; Fysh ETH; Smith NA; Lee P; Kwan BCH; Yap E; Horwood FC; Piccolo F; Lam DCL; Garske LA; Shrestha R; Kosky C; Read CA; Murray K; Lee YCG
JAMA; 2017 Nov; 318(19):1903-1912. PubMed ID: 29164255
[TBL] [Abstract][Full Text] [Related]
6. Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases.
Barbetakis N; Asteriou C; Papadopoulou F; Samanidis G; Paliouras D; Kleontas A; Lyriti K; Katsikas I; Tsilikas C
J Cardiothorac Surg; 2010 Apr; 5():27. PubMed ID: 20403196
[TBL] [Abstract][Full Text] [Related]
7. Povidone-iodine pleurodesis versus talc pleurodesis in preventing recurrence of malignant pleural effusion.
Ibrahim IM; Dokhan AL; El-Sessy AA; Eltaweel MF
J Cardiothorac Surg; 2015 May; 10():64. PubMed ID: 25947235
[TBL] [Abstract][Full Text] [Related]
8. Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH.
Aelony Y; King RR; Boutin C
Chest; 1998 Apr; 113(4):1007-12. PubMed ID: 9554639
[TBL] [Abstract][Full Text] [Related]
9. [The thoracoscopic talc pleurodesis with intraoperative pleural biopsy - a retrospective analysis in patients with malignant pleural effusion].
Hoksch B; Seidel N; Beshay M; Schmid RA
Zentralbl Chir; 2010 Feb; 135(1):54-8. PubMed ID: 20029741
[TBL] [Abstract][Full Text] [Related]
10. The significance of thoracoscopic mechanical pleurodesis for the treatment of malignant pleural effusions.
Crnjac A
Wien Klin Wochenschr; 2004; 116 Suppl 2():28-32. PubMed ID: 15506307
[TBL] [Abstract][Full Text] [Related]
11. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study.
Stefani A; Natali P; Casali C; Morandi U
Eur J Cardiothorac Surg; 2006 Dec; 30(6):827-32. PubMed ID: 17113008
[TBL] [Abstract][Full Text] [Related]
12. Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study.
Korsic M; Badovinac S; Cucevic B; Janevski Z
Wien Klin Wochenschr; 2015 Dec; 127(23-24):963-9. PubMed ID: 25860847
[TBL] [Abstract][Full Text] [Related]
13. Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results.
Basso SM; Mazza F; Marzano B; Santeufemia DA; Chiara GB; Lumachi F
Anticancer Res; 2012 Nov; 32(11):5131-4. PubMed ID: 23155293
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.
Kolschmann S; Ballin A; Gillissen A
Chest; 2005 Sep; 128(3):1431-5. PubMed ID: 16162739
[TBL] [Abstract][Full Text] [Related]
15. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma.
Crnjac A; Sok M; Kamenik M
Eur J Cardiothorac Surg; 2004 Aug; 26(2):432-6. PubMed ID: 15296910
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors of 30-Day Mortality After Palliative Procedures in Patients with Malignant Pleural Effusion.
Abrao FC; de Abreu IR; Fogarolli M; Caxeiro G; Bezerra CB; de Cerqueira Cesar FP; Rocha PS; Younes RN
Ann Surg Oncol; 2015 Nov; 22(12):4083-8. PubMed ID: 25758190
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status?
Abrao FC; Peixoto RD; de Abreu IR; Janini MC; Viana GG; de Oliveira MC; Younes RN
J Surg Oncol; 2016 Apr; 113(5):570-4. PubMed ID: 26751412
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of outpatient pleurodesis in patients with recurrent malignant pleural effusion and low performance status.
Terra RM; Teixeira LR; Bibas BJ; Pego-Fernandes PM; Vargas FS; Jatene FB
Clinics (Sao Paulo); 2011; 66(2):211-6. PubMed ID: 21484035
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of medical thoracoscopy and thoracoscopic talc poudrage in patients with exudative pleural effusion.
Verma A; Taha A; Venkateswaran S; Tee A
Singapore Med J; 2015 May; 56(5):268-73. PubMed ID: 26034319
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14).
Boshuizen RC; Vd Noort V; Burgers JA; Herder GJM; Hashemi SMS; Hiltermann TJN; Kunst PW; Stigt JA; van den Heuvel MM
Lung Cancer; 2017 Jun; 108():9-14. PubMed ID: 28625655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
